At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 58 enrolled
Drug / intervention
Tranexamic Acid (TXA)drug
Likely dose
Tranexamic Acid (TXA) 1 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Reducing Hemarthrosis in Tibial Tubercle Osteotomy by the Administration of Intravenous Tranexamic Acid
In Brief
A Phase 4 clinical trial evaluating Tranexamic Acid (TXA) for Tibial Tubercle Osteotomy. Completed, enrolled 58 participants across 1 site.
Detailed Summary
The purpose of the proposed study is to evaluate the effects of administering intravenous tranexamic acid (TXA) to patients undergoing high tibial osteotomy (HTO) and tibial tubercle osteotomy (TTO) to minimize hemarthrosis within the knee joint and post operative pain and swelling.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTibial Tubercle Osteotomy
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
Enrollment StartJun 2018
First PostedJul 2018
Primary CompletionJun 2021
TodayJul 2026
First PostedJul 30, 2018
Enrollment StartJun 26, 2018
Primary CompletionJun 2, 2021
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 7.9 years ago
Interventions
Tranexamic Acid (TXA)drug
One gram of intravenous tranexamic acid (TXA) will be administrated before tourniquet inflation and before closure of the incision, as 1 g has been shown to be a safe amount with minimal side effects